Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

NCT04764084 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Breast Cancer
Gastric Adenocarcinoma
Cholangiocarcinoma
Pancreatic Cancer

Interventions

DRUG: Niraparib
DRUG: Anlotinib

Sponsor

Peking University Cancer Hospital & Institute